Skip to main content
    T

    Tela Bio Inc (TELA)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.76
    -0.06 (-7.13%)

    Market Cap: $37.06M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tela Bio Inc (TELA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Tela Bio reported revenue of $80.28M for the fiscal year ended Dec 31, 2025, up 15.8% from the year before. That year, net income was -$38.83M with a net margin of -48.4%, operating cash flow was -$28.22M and free cash flow was -$28.67M. The quarter ended Sep 30, 2026 had revenue of $18.96M and net income of -$9.30M.

    Revenue and Margins

    The operating margin was -42.0% in the fiscal year ended Dec 2025, the highest of the 5 years shown with an operating margin. Over the 8 years to Dec 2025, revenue grew from $4.25M, a compound annual rate of 44.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$80.28M+15.8%67.7%-42.0%-48.4%
    Dec 2024$69.30M+18.6%67.1%-49.2%-54.6%
    Dec 2023$58.45M+41.1%68.6%-75.4%-79.8%
    Dec 2022$41.42M+40.6%65.3%-94.2%-106.9%
    Dec 2021$29.46M+61.8%63.9%-100.0%-112.9%
    Dec 2020$18.21M+17.9%61.7%-138.8%-158.1%
    Dec 2019$15.45M+86.7%60.0%-124.1%-145.2%
    Dec 2018$8.27M+94.9%35.6%-214.9%-254.9%
    Dec 2017$4.25MN/A59.6%-398.7%-502.6%
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$80.28M$69.30M$58.45M$41.42M$29.46M$18.21M$15.45M$8.27M$4.25M
    Cost of revenue$25.55M$22.81M$17.96M$14.37M$10.65M$6.67M$6.17M$5.33M$1.71M
    Gross profit$54.34M$46.49M$40.11M$27.04M$18.81M$11.23M$9.27M$2.94M$2.53M
    Research and development$9.22M$8.81M$9.62M$8.94M$6.74M$4.25M$4.15M$4.34M$5.79M
    Operating income-$33.76M-$34.12M-$44.08M-$39.01M-$29.45M-$25.27M-$19.16M-$17.78M-$16.92M
    Net income-$38.83M-$37.84M-$46.66M-$44.30M-$33.28M-$28.79M-$22.43M-$21.09M-$21.33M
    EBITDA-$31.46M-$31.68M-$40.63M-$37.83M-$29.14M-$24.75M-$18.23M-$16.22M-$16.02M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$18.96M$19.29M$19.06M$20.87M$20.69M$20.20M$18.52M$17.65M$18.96M$16.09M$16.60M$17.00M
    Gross profit$12.31M$13.94M$12.52M$13.76M$13.97M$14.11M$12.51M$11.22M$12.86M$11.07M$11.34M$11.62M
    Operating income-$7.29M-$9.28M-$10.53M-$6.65M-$7.55M-$9.08M-$10.47M-$8.35M-$9.37M-$11.57M-$4.83M-$12.28M
    Net income-$9.30M-$11.26M-$12.27M-$9.04M-$8.60M-$9.92M-$11.26M-$9.21M-$10.37M-$12.60M-$5.66M-$12.89M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $55.65M exceeded cash and equivalents by $4.81M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$81.42M$86.57M$78.05M$67.86M$62.54M$86.46M$67.92M$27.23M$15.53M
    Current assets$75.58M$78.07M$71.73M$62.45M$59.05M$83.22M$64.33M$23.25M$14.35M
    Cash and equivalents$50.84M$52.67M$46.73M$42.02M$43.93M$74.39M$45.30M$17.28M$11.35M
    Total liabilities$75.11M$58.11M$59.17M$53.55M$42.45M$37.43M$36.96M$40.94M$123.70M
    Short-term debt$0$545.00K$565.00K$340.00KN/AN/AN/AN/A$905.00K
    Long-term debt$55.65M$41.12M$40.52M$39.92M$0$30.83M$30.24M$29.73M$3.61M
    Shareholder equity$6.31M$28.46M$18.88M$14.30M$20.10M$49.03M$30.96M-$137.86M-$108.17M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$49.49M$59.74M$69.89M$81.42M$61.59M$67.54M$77.25M$87.33M$53.02M$60.20M$71.84M$78.05M
    Total liabilities$74.07M$75.60M$75.09M$75.11M$60.03M$58.35M$59.13M$58.87M$59.29M$57.33M$57.45M$59.17M
    Cash and equivalents$22.66M$30.42M$39.54M$50.84M$29.71M$34.98M$42.83M$52.67M$17.30M$26.50M$37.14M$46.73M
    Shareholder equity-$24.58M-$15.87M-$5.20M$6.31M$1.56M$9.18M$18.12M$28.46M-$6.27M$2.87M$14.38M$18.88M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$28.22M-$41.59M-$40.86M-$40.75M-$30.43M-$24.46M-$25.52M-$19.92M-$16.37M
    Capital expenditures$448.00K$989.00K$611.00K$872.00K$627.00K$167.00K$197.00K$62.00K$114.00K
    Free cash flow-$28.67M-$42.58M-$41.47M-$41.62M-$31.06M-$24.62M-$25.72M-$19.99M-$16.48M
    Share repurchasesN/AN/AN/AN/AN/A$522.00K$0$0N/A
    Investing cash flow$846.00K$4.45M-$599.00K-$1.87M-$627.00K$9.12M-$11.98M-$1.56M-$101.00K
    Financing cash flow$25.75M$43.06M$46.27M$40.85M$585.00K$44.41M$65.53M$27.41M$26.34M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$8.69M-$9.38M-$11.17M-$4.87M-$5.72M-$7.91M-$9.72M-$7.53M-$8.98M-$10.70M-$14.38M-$11.05M
    Capital expenditures$7.00K$59.00K$119.00K$91.00K$211.00K$114.00K$32.00K$264.00K$122.00K$299.00K$304.00K$205.00K
    Free cash flow-$8.70M-$9.44M-$11.29M-$4.96M-$5.93M-$8.02M-$9.76M-$7.79M-$9.11M-$11.00M-$14.69M-$11.26M
    Last 12 quarters

    Frequently Asked Questions About TELA

    What is Tela Bio's annual revenue?

    Tela Bio reported revenue of $80.28M for the fiscal year ended Dec 31, 2025.

    How fast is Tela Bio's revenue growing?

    Revenue was up 15.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 24.7%.

    Is Tela Bio profitable?

    No. Tela Bio reported net income of -$38.83M for the fiscal year ended Dec 31, 2025, with a net margin of -48.4%.

    How much free cash flow does TELA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$28.22M minus capital expenditures of $448.00K produced free cash flow of -$28.67M.

    How much debt does Tela Bio have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $55.65M, short-term debt of $0 and cash and equivalents of $50.84M.